Cannabis is a vastly underutilized therapeutic option that has been wrongly vilified by U.S. regulatory agencies. In this interview, Dr. Margaret Gedde, a Stanford-trained pathologist and award-winning researcher, discusses the therapeutic value of this plant.
While initially focused on the conventional medical model, Gedde eventually transitioned over to holistic, drug-free health care in 2004. At present, she runs an alternative medical practice in Colorado, the home of medical marijuana, as it was one of the first states to widely legalize and apply it.
Gedde specializes in the use of cannabis, especially for the use of pain, thereby allowing her patients to get off dangerous drugs like opiates, which have created a public health emergency of massive proportions.
Drug Enforcement Administration Just Took a Huge Step Backward
We’ve come a long way in the U.S. when it comes to re-normalizing the use of medicinal marijuana. Unfortunately, the Drug Enforcement Administration (DEA) is still trying to suppress it as best they can.
This despite the fact that CBD has no psychoactive component, meaning it cannot render you “high.” This is truly tragic when you consider the many medical uses for CBD. As noted by Gedde:
“It has been a real boon to have CBD available … CBD is not only non-psychoactive, it is remarkably non-toxic. Far less toxic than even over-the-counter medications that are commonly used.
The concept of putting CBD on the Schedule 1 of the drug schedule, saying that it has no medical use and is highly dangerous, just flies in the face of fact, science and knowledge. It’s such a regressive move. It’s certainly very disappointing …
[W]ith this move, they’re not going in the right direction at all. They’re definitely going backward. It’s like a hostile act.”
Indeed, the decision is so beyond irrational, the only justification I can see is that the DEA is influenced or controlled by the pharmaceutical industry. Making CBD — a non-psychoactive, non-toxic component with medicinal value — a schedule 1 drug benefits no one except the drug companies that have to compete against it.
There’s absolutely no justification in a rational, science-based system for this decision. Ironically, synthetic tetrahydrocannabinols (THC) drugs, such as Dronabinol and Marinol, are listed as Schedule 3 drugs.